Clinical Trials
29 trialsTislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
Shandong Public Health Clinical Center
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
Second Affiliated Hospital of Zunyi Medical University
Local Injection and Systemic Therapy in the Treatment of NSCLC.
Henan Cancer Hospital
Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy
The First Affiliated Hospital of Xinxiang Medical College
FTANLCNDG
Qianfoshan Hospital
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Anhui Chest Hospital
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
Second Xiangya Hospital of Central South University
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
Qilu Hospital of Shandong University
PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
RELIEF
Shanghai Chest Hospital
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Zhejiang Cancer Hospital
Endostar First-line Treatment of Advanced NSCLC
China Medical University, China
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Endostar Plus EGFR-TKI(Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor) as a Treatment of EGFR Mutation-positive NSCLC
Air Force General Hospital of the PLA
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Anhui Provincial Hospital
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage â…¢A NSCLC
Tianjin Medical University Cancer Institute and Hospital
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Zhejiang University
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.
Peking University Third Hospital
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
Zhejiang University
Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
Sun Yat-sen University
DP-EN-RT
Sun Yat-sen University
Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Simcere Pharmaceutical Co., Ltd
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
Fudan University
Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)
Zhejiang Cancer Hospital
Dengshan
Shanghai Jiao Tong University School of Medicine
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Chinese Academy of Sciences
NSCLC
Simcere Pharmaceutical Co., Ltd